

Evaluation of probiotics and prebiotics in food



Faculty of Agrobiological Sciences, Food and Natural Resources
Department of Microbiology, Nutrition and Dietetics

Vera Bunesova

MICROBIOTA - 'MICROFLORA OF THE BODY'



- ✓ Humans have got approximately **10^{13} cells of their body.**
- ✓ Humans have got around **10^{14} bacterial cells in/on their body.**
- ✓ Members of groups such as **viruses, fungi and protozoa** are also regularly found in healthy individuals, but form only a minor component of the total population of resident organisms.
- ✓ The microorganisms occur in parts of the body that are exposed to / or communicate with the external environment (the skin, nose and mouth, and intestinal and uriogenital tracts etc.).
- ✓ **The majority of bacterial cells is associated with the gastrointestinal tract.**
- ✓ **Internal organs and tissues are normally sterile.**

Intestinal mikrobiota – forgotten organ

10^{14} of bacterial cells

60 – 70 % of immune system cells

100 million of nervous cells

approximate surface **300 m²**



BENEFITS OF MICROBIOTA FOR THEIR HOST

Structural functions:

- Barrier fortification
- Induction of IgA
- Apical tightening of tight junctions
- Immune system development


Protective functions:

- Pathogen displacement
- Nutrient competition
- Receptor competition
- Production of anti-microbial factors
e.g., bacteriocins, lactic acids

Metabolic functions:

- Control intra epithelial cell differentiation and proliferation
- Metabolize dietary carcinogens
- Synthesize vitamins e.g., biotin, folate
- Ferment non-digestible dietary residue and endogenous epithelial derived mucus
- Ion absorption

BACTERIAL COLONIZATION OF THE GASTROINTESTINAL TRACT



MOUTH




ANUS

- ✓ Number of bacterial CFU is caudally increasing
- ✓ Number of **aerobic** bacteria is caudally decreasing
- ✓ Number of **anaerobic** bacteria is caudally increasing



CFU = Colony Forming Units


Intestinal microbiota - FISH



Health effect of predominant intestinal bacteria

Harmful/pathogenic effects

Health promoting functions



The gut microbiota through different life-stages

S.H. Duncan, H.J. Flint / *Maturitas* 75 (2013) 44–50






Fig. 1. Schematic summarising changes in the composition of the gut microbiota through different life-stages.


The colonization of the intestine




The colonization of the intestine



Changes in faecal flora during life (Mitsuoka, 1992)



The colonization of the intestine



Infant formula




FETUS
placental
microbiome


BIRTH
1. Contact
with
vaginal-,
intestinal-,
skin-flora

**BREAST
MILK/
INFANT
FORMULA**



Jakub (vaginal delivery, breast-fed)




Kateřina (cesarean section, bottle-fed)




Infant faeces stained by the FISH procedure using
bifidobacteria-specific (A) and clostridia-specific (B) probes



The colonization of the intestine




Changes in faecal flora during life (Mitsuoka, 1992)



Probiotics - definition

„Life microorganisms, which, when administered in adequate amounts confer a health benefit on the host“

(Hill et al., Nat Rev Gastro Hepat 2014)



Probiotic bacteria

Lactic acid bacteria

Lactobacillus acidophilus

Lactobacillus casei

Lactobacillus rhamnosus

Lactobacillus salivarius

Lactobacillus plantarum


Lactobacillus delbrueckii ssp. *bulgaricus*

Lactococcus lactis

Enterococcus faecium

Streptococcus thermophilus

Pediococcus pentosaceus



Bifidobacteria

Bifidobacterium animalis ssp. *lactis*

Bifidobacterium longum

Bifidobacterium bifidum

Bifidobacterium breve

Bifidobacterium infantis

Bifidobacterium pseudolongum

Bifidobacterium thermophilum

Other bacteria

Escherichia coli

Bacillus sp.

Clostridium butyricum

Fungi


Saccharomyces sp.

Aspergillus oryzae


Candida pintolopesii

Mechanisms of Probiotic Action

- Adhesion to intestinal mucus and epithelium
- Aggregation and coaggregation
- Production of antimicrobial substances
- Nutritional effects
- Prevention and treatment of diarrhea
- (Antitumor effects, treatment/prevention of allergic diseases, inflammatory bowel diseases, infection of respiratory tract, etc.)



Adherence to epithelial cells (Kmet, 2004)



Coaggregation

Nutritional effects

- Alleviation of lactose intolerance symptoms (β -galactosidase; approved by EFSA)
- Production of vitamins (B, K)
- Reduction of serum cholesterol

Production of antimicrobial substances

- Organic acids
- Hydrogen peroxide
- Bacteriocins (nisin E234, sakacin)
- Reuterin

Prevention and treatment of diarrhea

- Antibiotic-associated diarrhea (*Saccharomyces boulardii*)
- Traveler's diarrhea (prevention)
- *Clostridium difficile*-associated diarrhea (stool transplantation)

■ Treating recurrent *Clostridium difficile* infection by restoring healthy intestinal flora




FIGURE 1.

Guidelines for the evaluation of Probiotics for Food Use (FAO/WHO 2002)

Strain identification by phenotypic and genotypic methods. Genus, species, strain. Deposit strain in international culture collection



Functional characterization. In vitro tests. Animal studies



Safety assessment. In vitro and/or animal study. Phase 1 human study



Double blind, randomized, placebo-controlled (DBPC) phase 2 human trial



Preferable second DBPC



Phase 3, effectiveness trial is appropriate to compare probiotics with standard treatment



Probiotic Food



Labeling, content – genus, species, strain designation. Minimum numbers of viable bacteria at end of shelf-life. Proper storage conditions. Corporate contact details for consumer information.

Commercially available probiotic organisms

- *Lactobacillus acidophilus* LA5 (Chr. Hansen)
 - *Lactobacillus rhamnosus* GG (LGG; ATCC 53103; Gefilus®)
 - *Lactobacillus casei* Shirota (Yakult)
 - *Lactobacillus casei* Imunitass (Danone)
-
- *Bifidobacterium animalis* subsp. *lactis* DN173010 (Danone)
 - *Bifidobacterium animalis* subsp. *lactis* BB 12 (Chr. Hansen)
 - *Bifidobacterium longum* BB536 (Murinaga)
 - *Bifidobacterium breve* (Yakult)

Commercially available probiotic organisms




Effective dosage for probiotic effect?

- Daily dose (10^7 - 10^{10} CFU)
- Daily frequency of administration (1-4 times)
- Timing of administration
- Duration of administration (1day – several months)
- Method of delivery (fermented food, beverages, capsule, tablet)
- Viability


Prebiotics - definition

„Nondigestible food ingredients that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon and thus improves host health“ (Gibson and Roberfroid, 1995) (Inulin, soya oligosaccharides)



Criteria for Prebiotics (Roberfroid, 2007)

- resistance to gastric acidity, to hydrolysis by mammalian enzymes, and to gastrointestinal absorption
- fermentation by intestinal microbiota
- selective stimulation of the growth and/or activity of those intestinal bacteria that contribute to health and well-being



Prebiotics

- FOS – fructooligosaccharides
- GOS – galactooligosaccharides
- SOS – soya oligosaccharides
- XOS – xylooligosaccharides
- MOS – isomaltooligosaccharides
- HMOs – human milk oligosaccharides



Inulin content in selected plants (Ebringer, 2002)

<u>Plant</u>	<u>inulin (FOS) content in g/100g</u>
Onion	2 – 7
Garlic	9 – 16
Leek	3 – 10
Sweet potatoes	13 – 20
Jerusalem artichoke	16 – 40
Dandelion	12 – 15
Banana	0.3 – 0.7

